Aurobindo Pharma is planning to build three new plants in India to prep for more launches in the U.S. market and to make India its sourcing hub for its Western European generic drug business acquired from Actavis last year.
The $150 million projects include an oral solid finished dose facility in Naidupet (Andhra Pradesh), oral finished dose facility for European markets in Visakhapatnam (Andhra Pradesh) and a new semi-synthetic penicillin plant near Hyderabad.
Aurobindo has filed 379 ANDAs as of June 30 and to date has 208 approvals. The company recently received U.S. FDA approval for manufacturing and marketing Ibandronate Sodium injection -- a bio-equivalent osteoporosis drug for Roche's Boniva -- and Omeprazole Delayed-release capsules -- a bio-equivalent for AstraZeneca's Prilosec.
Read the Live Mint article